J&J/Basilea ceftobiprole positive Phase III data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Swiss firm Basilea announces positive results for its first-in-class antibiotic ceftobiprole. The antibiotic met its primary endpoint of statistical noninferiority versus combination therapy in complicated skin and skin structure infections (cSSSIs) in a second pivotal Phase III trial (STRAUSS II) in resistant Staphylococcus aureus skin infections. Data indicate that single-agent ceftobiprole was as effective as a combination regimen of standard broad-spectrum agents, the company said. Johnson & Johnson licensed rights to the broad-spectrum cephalosporin from Basilea in February 2005 (1Pharmaceutical Approvals Monthly February 2005, p. 19)...
You may also be interested in...
J&J, Basilea To File Ceftobiprole For Hospital-Acquired Pneumonia
Basilea Pharmaceuticals plans to file the antibiotic ceftobiprole "as soon as possible" for the treatment of hospital-acquired pneumonia and community-acquired pneumonia requiring hospitalizations following positive Phase III results, CEO Anthony Man stated during an Oct. 9 conference call announcing the results
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.